Preview Mode Links will not work in preview mode

Jun 17, 2021

Featuring Dr Courtney D DiNardo’s perspectives on her time spent speaking with patients with acute myeloid leukemia from the practices of community oncologists Drs KS Kumar and Andrew C Rettew, including the following topics:

  • Case: A woman in her early 70s with acute myeloid leukemia (AML) and an IDH mutation receives venetoclax and azacytidine (0:00)
  • Selection of patients for treatment with venetoclax/azacitidine versus intensive 7 + 3 chemotherapy; optimal application of venetoclax/azacytidine (5:41)
  • Tolerability and side effects of venetoclax/azacitidine; testing for IDH mutations and choice of therapy for patients with AML and an IDH mutation (14:24)
  • Duration of therapy and long-term outcomes with venetoclax/azacitidine; clinical research on combination therapy with venetoclax and oral hypomethylating agents (HMAs) (23:08)
  • Treatment options for patients with AML who experience disease progression on venetoclax/azacitidine; use of IDH inhibitors for AML (29:23)
  • Case: A woman in her mid-50s with a complex medical history is diagnosed with AML and receives 7 + 3 chemotherapy and gemtuzumab ozogamicin (34:24)
  • Case: A man in his early 70s with AML and a FLT3-ITD mutation receives 7 + 3 chemotherapy and midostaurin (47:36)
  • Optimal approach to the management of AML with FLT3 mutations (51:20)
  • Impact of COVID-19 on the clinical care of patients with AML (57:37)
  • Case: A man in his early 70s with AML with myelodysplasia-related changes and mutations in RUNX1, SRSF2, ASXL1 and IDH2 receives liposomal daunorubicin and cytarabine (CPX-351) followed by enasidenib (1:07:10)
  • Activity and tolerability of CPX-351 for AML; patient selection (1:11:19)
  • Choice between a venetoclax/HMA combination and an IDH inhibitor for patients with progressive AML and an IDH mutation (1:17:53)
  • Feasibility and efficacy of stem cell transplantation in patients with relapsed AML; use and tolerability of glasdegib and low-dose cytarabine for AML (1:25:52)

CME information and select publications